Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity

Clinical Infectious Diseases

Volumn 50, Issue 6, 2010, Pages 833-839

  Sharma, Surendra K ^a   Singla, Rohit ^a   Sarda, Pawan ^a   Mohan, Alladi ^b   Makharia, Govind ^a   Jayaswal, Arvind ^a   Vishnubhatla Sreenivas, J ^a   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; SERUM ALBUMIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTITUBERCULOSIS DRUG REINTRODUCTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOGRAPHY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HEPATITIS; HUMAN; INDIA; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MILIARY TUBERCULOSIS; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 77749245930     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650576     Document Type: Article

References (24)

1. 1. Schaberg T, Rebhan K, Lode H. Risk factors for side effects of isoniazidrifampicin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030. (Pubitemid 26333539)
2. Dash LA, Comstock GW, Flynn PG. Isoniazid preventive therapy: retrospect and prospect. Am Rev Respir Dis 1980; 121: 1039-1044.
3. 3. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to anti-tuberculosis therapy: clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996; 22: 211-214. (Pubitemid 26118626)
4. 4. Tahaoglu K, Ataç G, Sevim T, et al. The management of anti-tuberculosis drug induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-69. (Pubitemid 32401878)
5. 5. Agal S, Baijal. R, Pramanik S, et al. Monitoring and management of anti-tuberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005; 20: 1745-1752. (Pubitemid 43961083)
6. 6. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166: 916-919. (Pubitemid 35193218)
7. 7. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136. (Pubitemid 26060649)
8. 8. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996; 77: 37-42. (Pubitemid 26066608)
9. 9. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477. (Pubitemid 37363354)
10. 10. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77: 335-340. (Pubitemid 26258538)
11. 11. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002; 6: 699-705. (Pubitemid 34832150)
12. Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamidc-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12: 87-91.
13. 13. Ohkawa K, Hashiguchi M, Ohno K, et al. Risk factors for antituberculous chemotherapyinduced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002; 72: 220-226. (Pubitemid 35034500)
14. National tuberculosis association of the U.S.A. Diagnostic standards and classification of tuberculosis. New York: National Tuberculosis Association, 1961.
15. Saukkonen JJ, Cohn DL, Jasmer RM, et al on the behalf of ATS Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
16. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom. Thorax 1998; 53: 536-548.
17. TBC India Web page. Directorate General of Health Services Ministry of Health and Family Welfare, http://www.tbcindia.org. Accessed 8 February 2010.
18. World Health Organization (WHO). Treatment of tuberculosis: Guidelines for national programmes. 2nd ed. Geneva, Switzerland: WHO, 1997; 25-39.
19. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing; Geneva, Switzerland: WHO, 2007.
20. 20. Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K, Jain SK. Adverse drug reactions observed during DOTS. J Commun Dis 2004; 36: 251. (Pubitemid 43116792)
21. Hong Kong Chest Service/British Medical Research Council. First report: Controlled trial of four thrice weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet 1981; 1: 171-174.
22. Shakya R, Rao BS, Shrestha B. Management of antitubercular drugsinduced hepatotoxicity and therapy reintroduction strategy in a TB clinic of Nepal. Kathmandu Univ Med J (KUMJ) 2005; 3: 45-49.
23. Sarda P, Sharma SK, Mohan A, et al. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009; 129: 64-67.
24. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India 2006; 19: 203-217.